Oxycodone addiction treatment is not a last resort. It is a well-documented, evidence-based path that tens of thousands of people in Maryland walk every year, and the outcomes data is clear: treatment works, recovery is real, and the process is more structured and human than most people expect before they start.
What Oxycodone Addiction Actually Is
Opioid use disorder is a diagnosable medical condition, not a failure of willpower or character. The DSM-5 defines it by a cluster of behavioral and physiological criteria: continued use despite harm, inability to cut down despite wanting to, cravings that interfere with daily functioning, and tolerance or withdrawal when use stops. Meeting two or more of those criteria within a twelve-month period constitutes opioid use disorder, regardless of whether the opioid in question was prescribed by a physician or obtained otherwise.
The stakes are not abstract. The CDC’s 2023 data attributes more than 80,000 opioid-related overdose deaths in the United States to a single year, with oxycodone and other prescription opioids playing a significant role alongside illicit fentanyl. Maryland consistently ranks among the states with the highest per-capita opioid overdose rates.
What the data also shows is that treatment dramatically changes those outcomes. A 2021 analysis published in the Annals of Internal Medicine found that patients engaged in medication-assisted treatment had a 59% lower risk of all-cause mortality compared to those not in treatment. Recovery is not a hope. It is a documented destination.
How Oxycodone Dependence Develops
Oxycodone binds to opioid receptors in the brain’s reward circuitry, triggering a release of dopamine that is far more intense than anything produced by ordinary pleasurable activities. With repeated use, the brain adapts. It reduces its natural dopamine production and recalibrates its baseline, meaning everyday experience begins to feel flat, and oxycodone begins to feel necessary just to feel normal. This process is neurological adaptation, not weakness.
A 2010 study published in the journal Neuropsychopharmacology demonstrated that chronic opioid exposure leads to measurable changes in the prefrontal cortex, the region governing decision-making and impulse control. This is why people with opioid use disorder often describe knowing intellectually that they need to stop while feeling unable to act on that knowledge. The brain’s control mechanisms are functionally impaired.
Stopping oxycodone without medical support does not reverse this quickly. The withdrawal process is physically intense, and without supervision, the risk of returning to use just to relieve symptoms is high. Unsupervised detox is not a safe strategy, and it is not covered further here because it should not be attempted alone.
The Difference Between Dependence and Addiction
Physical dependence and opioid use disorder are related but not the same thing. Physical dependence means the body has adapted to the presence of the drug and will respond with withdrawal symptoms when it is reduced or stopped. This happens to anyone who takes opioids regularly over time, including surgical patients and those managing chronic pain with a legitimate prescription.
Opioid use disorder adds compulsive use and continued use despite harm. Someone physically dependent on oxycodone after a surgery may be able to taper off with medical guidance and move on without issue. Someone with opioid use disorder faces a different pattern entirely. This distinction matters because it shapes the treatment approach. Dependence alone may require a supervised taper. Opioid use disorder requires a more comprehensive treatment plan that addresses the neurological and behavioral dimensions of the condition.
Warning Signs That Use Has Crossed Into Addiction
The clearest signals are behavioral shifts that start to affect daily life. Using more oxycodone than prescribed, or using it differently than prescribed, is an early marker. So is spending significant time obtaining, using, or recovering from the drug. Neglecting responsibilities at work, home, or school; withdrawing from relationships; continuing to use despite knowing it is causing health or financial problems; these are the patterns that clinicians assess.
Physically, you may notice tolerance building, meaning the same dose produces less effect over time. Withdrawal symptoms when doses are missed, including sweating, restlessness, muscle aches, nausea, and anxiety, signal that physical dependence has developed. Psychologically, preoccupation with the next dose and difficulty experiencing pleasure without the drug are characteristic markers.
Families often notice changes in mood, sleep patterns, financial behavior, and social withdrawal before the person using recognizes the pattern themselves. These are clinical signals that a medical evaluation is warranted, not character judgments.
The First Step: Medical Detox and Withdrawal Management
Oxycodone withdrawal follows a predictable timeline. Symptoms typically begin eight to twenty-four hours after the last dose, peak between forty-eight and seventy-two hours, and begin to resolve after five to seven days for most people, though psychological symptoms like anxiety, insomnia, and low mood can persist for weeks.
The physical symptoms during peak withdrawal are significant: severe muscle cramping, sweating, chills, vomiting, diarrhea, insomnia, and intense drug cravings. SAMHSA’s clinical guidelines identify dehydration from vomiting and diarrhea as a genuine medical risk during unsupervised withdrawal, particularly in older adults and those with cardiovascular conditions. The risk of relapse during this period is also extremely high. Most people who attempt to stop on their own return to use within days, often using the same dose they previously tolerated, which dramatically increases overdose risk.
Medically supervised detox eliminates those risks. It is not a luxury or an extra step. It is the safe foundation on which the rest of treatment is built.
What to Expect During Supervised Detox
A supervised detox stay typically runs five to seven days for oxycodone. On arrival, clinical staff conduct a full medical assessment: vitals, health history, co-occurring conditions, and current substance use. This assessment guides the medication and monitoring protocol for the days ahead.
During detox, you are monitored regularly throughout the day. Comfort medications manage the most difficult symptoms: anti-nausea agents, medications for muscle cramping, non-opioid options for anxiety and sleep. If buprenorphine is appropriate as an ongoing medication, the induction process begins once you are in a defined withdrawal state. The goal during detox is stabilization, meaning getting you physically comfortable enough to engage meaningfully in the next phase of treatment.
Detox is not treatment in itself. It is the entry point. What follows determines long-term outcomes.
Medications Used to Treat Oxycodone Addiction
Medication-assisted treatment (MAT) is the evidence-based standard of care for opioid use disorder. NIDA’s position, supported by decades of clinical trial data, is unambiguous: medications for opioid use disorder reduce illicit drug use, lower overdose mortality, decrease criminal activity, and improve treatment retention. Framing MAT as substituting one addiction for another reflects a misunderstanding of the pharmacology, and that misunderstanding costs lives.
In Maryland, MAT is available across Medicaid and most commercial insurance plans, with Medicaid covering buprenorphine without prior authorization. For those exploring what structured support looks like across the state, Maryland’s options for opioid use disorder have expanded significantly in the last several years.
Buprenorphine (Suboxone)
Buprenorphine is a partial opioid agonist, meaning it activates opioid receptors but with a ceiling effect. Above a certain dose, the effect does not increase. This is what makes it safe for office-based prescribing. It reduces cravings and eliminates withdrawal without producing the euphoric high that drives compulsive use.
A landmark 2014 Cochrane Review analyzing 31 randomized controlled trials found that buprenorphine was significantly more effective than placebo at retaining patients in treatment and suppressing illicit opioid use. Retention in treatment is itself a primary outcome measure because staying in treatment is what reduces mortality.
Buprenorphine is often prescribed as Suboxone, a combination formulation that includes naloxone to deter injection misuse. Following the removal of the federal X-waiver requirement in 2023, any DEA-licensed prescriber can now prescribe buprenorphine for opioid use disorder, which has meaningfully expanded access. Office-based prescribing means you do not need to attend a specialized clinic daily.
Methadone
Methadone is a full opioid agonist with a long half-life, meaning it produces a steady, sustained effect that eliminates withdrawal and cravings without the peaks and valleys of shorter-acting opioids. It has been used to treat opioid use disorder since the 1960s, and the evidence base is extensive.
A 2009 Cochrane Review of methadone maintenance treatment found that patients receiving methadone were significantly more likely to stay in treatment and significantly less likely to use heroin compared to those receiving no medication. The reduction in illicit drug use is the primary mechanism through which methadone reduces overdose risk.
Because methadone is a full agonist with a complex pharmacology, it is dispensed through federally licensed opioid treatment programs (OTPs) rather than standard pharmacies. Initially, this means daily attendance for dosing. As trust and stability build over time, take-home doses become available. For those whose opioid use disorder involves heroin or fentanyl, structured treatment programs that include methadone as an option can be an appropriate starting point when office-based buprenorphine is not the right fit.
Naltrexone (Vivitrol)
Naltrexone works differently from buprenorphine and methadone. It is an opioid antagonist, meaning it completely blocks opioid receptors. If you take an opioid while on naltrexone, you feel nothing. There is no partial effect, no ceiling, no opioid activity at all. This makes it effective as a relapse prevention tool for people who are already fully detoxed and motivated to maintain abstinence.
The injectable form, Vivitrol, is administered once monthly by a clinician. A 2011 randomized controlled trial published in The Lancet found that extended-release injectable naltrexone significantly reduced opioid-positive urine tests and increased abstinent days compared to placebo among patients with opioid use disorder. The monthly injection removes the daily decision about whether to take a pill, which is a meaningful adherence advantage over oral naltrexone.
The clinical requirement before starting naltrexone is complete opioid clearance, typically seven to ten days without any opioids. Starting too early triggers immediate, severe withdrawal. Naltrexone suits patients with strong social support, stable housing, and high motivation for full abstinence.
Lofexidine and Non-Opioid Comfort Medications
Lofexidine, sold as Lucemyra, is the first non-opioid medication approved by the FDA specifically for the management of opioid withdrawal symptoms. It works on the nervous system to reduce the physical symptoms of withdrawal, including sweating, muscle aches, and restlessness, without acting on opioid receptors at all.
During detox, clinicians commonly use a range of adjunct medications: clonidine for autonomic withdrawal symptoms, anti-nausea medications for gastrointestinal distress, and non-habit-forming sleep aids for insomnia. These medications do not address cravings or the neurological underpinnings of opioid use disorder. Their role is symptom management during the acute detox phase, making it physically possible to engage in the transition to long-term treatment.
Are Medications for Opioid Use Disorder Addictive?
This is the question that keeps more people out of treatment than almost any other. The answer, based on the clinical evidence, is no, not in the way the concern implies.
NIDA distinguishes clearly between physical dependence and addiction. A person stabilized on buprenorphine has adapted to the medication physically, but they are not compulsively seeking it, escalating the dose against medical advice, or experiencing harm from its use. The same distinction applies to someone taking a beta-blocker for heart disease. Dependence on a medication that is working is not addiction.
A 2016 study published in Drug and Alcohol Dependence analyzed patients on buprenorphine maintenance and found that the medication normalized brain function in the prefrontal regions impaired by chronic opioid use. Far from sustaining a diseased state, effective MAT supports neurological recovery.
The stigma around MAT is not a neutral opinion. It has measurable consequences. Patients who internalize that stigma or who are denied MAT by providers with ideological objections to it have significantly worse treatment outcomes. The data on this is not ambiguous.
Levels of Care: Matching Treatment to Need
The American Society of Addiction Medicine (ASAM) developed a placement criteria framework that matches patients to care settings based on clinical need, not on assumptions about severity or moral standing. The criteria assess six dimensions: withdrawal risk, biomedical conditions, emotional and behavioral conditions, readiness to change, relapse potential, and recovery environment. Where you fall across those dimensions determines the appropriate starting point, and that assessment is done by a clinician, not by you filling out a form online.
This matters because oxycodone addiction treatment is not one-size-fits-all. Two people presenting with opioid use disorder can have very different clinical needs, and placing someone in a less intensive setting than they need is as problematic as placing someone in a more intensive setting than necessary.
Residential Inpatient Treatment
Residential treatment is appropriate when the recovery environment at home is unsafe or unsupportive, when co-occurring mental health conditions require intensive stabilization, when prior outpatient attempts have not succeeded, or when the severity of dependence warrants round-the-clock medical oversight. A residential stay typically runs twenty-eight to ninety days, depending on clinical progress.
The structure of residential treatment includes daily individual and group therapy sessions, medication management, psychoeducation about opioid use disorder and recovery, and, in quality programs, treatment for co-occurring conditions. The environment removes you from the triggers and stressors of daily life during the period when those triggers carry the most risk. For people managing prescription painkiller dependence alongside untreated anxiety or depression, residential treatment often provides the first opportunity to address both simultaneously.
Partial Hospitalization Programs (PHP) and Intensive Outpatient Programs (IOP)
PHP and IOP are structured treatment programs that allow patients to live at home while receiving intensive therapeutic support. PHP typically involves five to six hours of programming per day, five days a week. IOP is less intensive, usually nine to twelve hours per week across three to four days. Both serve as step-down options from residential treatment or as starting points for patients with stable housing and a supportive home environment.
For patients who cannot take extended time away from work or family, IOP often makes treatment accessible in a way residential care cannot. The clinical content is comparable: group therapy, individual counseling, medication management, and relapse prevention skills. The key clinical requirement is that home is a recovery-supportive environment. If that condition is not met, a higher level of care is the right call.
Standard Outpatient Treatment
Standard outpatient care is the maintenance phase of treatment: regular appointments with a prescribing provider, ongoing MAT, and continued counseling, typically one to two sessions per week or less. For those who have completed a higher level of care and achieved stabilization, outpatient engagement is what sustains recovery over the months and years ahead.
Long-term outpatient engagement matters more than most people expect before they start treatment. The research on opioid use disorder consistently shows that longer duration of treatment engagement is associated with better outcomes. A six-month treatment episode produces better results than a thirty-day episode, and a two-year episode produces better results than six months.
The Role of Counseling and Behavioral Therapy
Medication stabilizes the neurological foundation. Counseling builds on top of it. For most people with opioid use disorder, medication alone is not sufficient for sustained recovery because the patterns of thinking, the unresolved trauma, the coping deficits, and the social circumstances that shaped drug use do not resolve automatically when cravings are reduced.
A 2011 study published in JAMA Psychiatry compared patients receiving buprenorphine alone versus buprenorphine combined with behavioral therapy. At twelve months, the combined group showed significantly lower rates of opioid-positive urine samples and significantly higher rates of treatment retention. The medication creates the stability necessary to engage in therapy. The therapy creates the changes that sustain recovery when, eventually, the medication is tapered.
Cognitive Behavioral Therapy (CBT) for Opioid Use Disorder
CBT is one of the most evidence-supported behavioral interventions for opioid use disorder. The model is practical and skills-based. You work with a therapist to identify high-risk situations, the people, places, emotional states, and circumstances most strongly associated with drug use. You practice challenging the distorted thoughts that make relapse feel inevitable or justified. You build concrete skills for refusing use when cravings arise.
A 2017 Cochrane Review of CBT for substance use disorders found that CBT outperformed control conditions on several outcome measures, including reduced substance use and improved psychosocial functioning. What makes CBT particularly useful in opioid use disorder treatment is its focus on skill transfer: the strategies learned in session are designed to work in real-world situations outside the therapist’s office.
Contingency Management
Contingency management is a behavioral intervention with among the strongest evidence in the addiction treatment literature, and it remains significantly underused. The approach is straightforward: positive behaviors, such as negative drug tests or consistent attendance, are rewarded with tangible incentives. Vouchers, small cash equivalents, and prize draws have all been studied.
A 2006 meta-analysis published in Drug and Alcohol Dependence, which reviewed forty-seven studies with more than three thousand patients, found that contingency management produced large effect sizes for drug abstinence compared to control conditions. The mechanism makes neurological sense: during early recovery, when the brain’s reward system is dysregulated and natural rewards feel muted, external reinforcement provides the kind of reward signal the brain is not yet generating on its own. It is not bribery. It is a clinical tool that works.
Individual and Group Therapy
Individual therapy provides the space for personalized work: processing trauma histories that often underlie opioid use disorder, addressing co-occurring mental health conditions, repairing damaged relationships, and building a recovery identity. The therapeutic relationship itself, consistent, non-judgmental, and focused entirely on your progress, is a meaningful clinical factor.
Group therapy serves a different function. It reduces the isolation that frequently accompanies addiction, provides peer accountability, models recovery from people further along the path, and builds the social skills that may have atrophied during active use. In most residential and IOP settings, group therapy is the backbone of the daily schedule for a reason. The research on therapeutic communities and peer support consistently shows that social connection is a protective factor in sustained recovery.
Treating Co-Occurring Mental Health Conditions
SAMHSA’s 2020 National Survey on Drug Use and Health found that approximately 50% of people with a substance use disorder also meet criteria for a co-occurring mental health condition. Among people with opioid use disorder specifically, rates of depression, anxiety, PTSD, and trauma histories are the norm, not the exception.
This matters clinically because treating opioid use disorder in isolation, without addressing co-occurring conditions, produces measurably worse outcomes. Depression that goes untreated is a relapse risk factor. Untreated PTSD drives avoidance and emotional dysregulation that medication alone does not address. Integrated dual-diagnosis treatment, where addiction and mental health conditions are addressed in the same clinical setting by coordinating providers, is associated with better retention, lower relapse rates, and better quality of life outcomes than sequential or siloed care.
When evaluating treatment programs, integrated care is not a bonus feature. It is a marker of clinical quality.
Oxycodone Addiction Treatment During Pregnancy
Untreated opioid use disorder during pregnancy carries significant risks: preterm labor, fetal growth restriction, placental abruption, and neonatal opioid withdrawal syndrome (NOWS) from fluctuating opioid levels in the bloodstream. The American College of Obstetricians and Gynecologists (ACOG) and NIDA both recommend that opioid use disorder in pregnancy be treated with medication, not managed through abrupt discontinuation.
Abrupt cessation of opioids during pregnancy can precipitate withdrawal in the fetus and increase the risk of miscarriage or stillbirth. Buprenorphine and methadone are both recommended treatments during pregnancy. Both have been studied extensively in pregnant populations, and the data consistently shows that the risks of untreated opioid use disorder outweigh the risks of medication-assisted treatment.
Babies born to mothers on MAT may experience NOWS, a manageable condition characterized by irritability, feeding difficulties, and tremors. NOWS is treated in a neonatal care setting and resolves with appropriate medical management. It is not a reason to avoid treatment during pregnancy. It is a manageable clinical event that the medical team plans for in advance.
Why So Few People Access Treatment, and How to Change That
SAMHSA’s 2023 National Survey on Drug Use and Health estimated that approximately 6.1 million Americans met criteria for opioid use disorder in 2022. Of those, fewer than 25% received any form of specialty treatment. The gap is not explained by lack of desire. When surveyed, most people who did not access treatment cited stigma, cost, geographic barriers, fear of withdrawal, and distrust of the healthcare system.
Several of those barriers have shifted meaningfully in recent years. The removal of the X-waiver requirement in 2023 means any licensed prescriber can offer buprenorphine, not only addiction specialists. Telehealth prescribing for buprenorphine, expanded through federal policy during the COVID-19 pandemic and maintained since, means patients in rural Maryland or those without reliable transportation can access a prescribing provider without leaving home. Maryland Medicaid covers buprenorphine treatment without prior authorization, removing the administrative delay that once forced patients to wait weeks for approval.
For patients whose substance use involves fentanyl, which now dominates the illicit drug supply in Maryland, the clinical picture requires experienced prescriber oversight given fentanyl’s potency and the unpredictability of illicit supply. Structured fentanyl treatment programs that include medication management are available across the state. For those whose dependence developed through prescription painkillers, the path through treatment is the same, even if the origin story is different. Painkiller addiction treatment in Maryland addresses the same underlying neurology through the same evidence-based tools.
What Recovery Actually Looks Like Over Time
Recovery is not linear, and expecting it to be produces unnecessary shame when the trajectory wobbles. The clinical literature describes opioid use disorder as a chronic condition with an expected course: early instability, gradual stabilization, and longer-term rebuilding. A 2018 study published in Drug and Alcohol Dependence, which followed 1,800 people in recovery over five years, found that recovery quality improved significantly with time in treatment, and that at five years, the majority reported high levels of functioning across health, relationships, and employment.
Relapse, when it occurs, is not evidence that treatment has failed. It is a clinical event, comparable to a blood pressure spike in someone managing hypertension. The appropriate response is clinical: review what happened, adjust the treatment plan, and continue. People who return to treatment after a relapse and stay engaged achieve recovery outcomes comparable to those who did not relapse. The destination does not change because the path was not straight.
How to Support a Loved One Through Treatment
If you are reading this for someone else, the most useful distinction to understand is the difference between support and enabling. Support means helping someone access treatment, offering to accompany them to an appointment, and maintaining connection without conditions that create shame. Enabling means removing the natural consequences of continued drug use in ways that reduce the incentive to seek help.
Do not attempt to detox someone at home. The medical risks are real, and the relapse risk during unsupervised withdrawal is high. If someone you care about is ready to talk, the initial conversation works best when it is specific, non-judgmental, and focused on one concrete step: making an appointment, calling a program, finding out what insurance covers.
Community Reinforcement and Family Training, known as CRAFT, is an evidence-based approach for family members that teaches practical strategies for supporting a loved one toward treatment while protecting your own mental health. A 2016 meta-analysis found that CRAFT produced significantly higher rates of treatment entry among the person with the substance use disorder compared to Al-Anon or standard educational approaches. It is available through therapists trained in the model and through self-guided materials.
Finding Oxycodone Addiction Treatment in Maryland
Maryland Medicaid covers MAT without prior authorization for buprenorphine, which means cost is not a barrier to starting medication-assisted treatment for most Medicaid enrollees. Commercial plans vary, but most cover MAT under mental health parity laws. For those without any coverage, sliding-scale fee programs and publicly funded treatment slots exist across the state.
When you call a treatment provider, the questions worth asking are direct: Does the program offer MAT, specifically buprenorphine or methadone? Is behavioral therapy integrated into care, or is medication management a separate silo? Are co-occurring mental health conditions treated within the same program? Is telehealth available if in-person attendance is a barrier?
Telehealth-based buprenorphine prescribing is a real access option for patients across Maryland, including those in areas without a nearby provider or those managing transportation or work schedule constraints. The standard of care delivered via telehealth, when the platform and provider are appropriate, is equivalent to in-person care for stable opioid use disorder patients.
For those working through what opioid dependence treatment involves step by step, or for patients whose history involves both prescription opioids and other substances, treatment programs that address multiple opioid types across a single clinical relationship produce better outcomes than navigating multiple fragmented providers.
The one concrete action that changes outcomes this week: make a call. Not to research more, not to wait until circumstances feel more convenient. The evidence on treatment access is consistent: the longer the gap between recognizing the problem and contacting a provider, the harder the path. Maryland has the infrastructure, the coverage, and the clinical capacity to start treatment quickly. What it requires from you is one phone call to find out what is available.